Literature DB >> 26841783

Innate Immunity and Inflammation in NAFLD/NASH.

Marco Arrese1, Daniel Cabrera1,2, Alexis M Kalergis3, Ariel E Feldstein4,5,6.   

Abstract

Inflammation and hepatocyte injury and death are the hallmarks of nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), which is a currently burgeoning public health problem. Innate immune activation is a key factor in triggering and amplifying hepatic inflammation in NAFLD/NASH. Thus, identification of the underlying mechanisms by which immune cells in the liver recognize cell damage signals or the presence of pathogens or pathogen-derived factors that activate them is relevant from a therapeutic perspective. In this review, we present new insights into the factors promoting the inflammatory response in NASH including sterile cell death processes resulting from lipotoxicity in hepatocytes as well as into the altered gut-liver axis function, which involves translocation of bacterial products into portal circulation as a result of gut leakiness. We further delineate the key immune cell types involved and how they recognize both damage-associated molecular patterns or pathogen-associated molecular patterns through binding of surface-expressed pattern recognition receptors, which initiate signaling cascades leading to injury amplification. The relevance of modulating these inflammatory signaling pathways as potential novel therapeutic strategies for the treatment of NASH is summarized.

Entities:  

Keywords:  Cell death; Inflammation; Innate immunity; Liver disease; NASH; Therapy

Mesh:

Year:  2016        PMID: 26841783      PMCID: PMC4948286          DOI: 10.1007/s10620-016-4049-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  87 in total

Review 1.  Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.

Authors:  Alessandro Federico; Marcello Dallio; Justyna Godos; Carmela Loguercio; Federico Salomone
Journal:  Transl Res       Date:  2015-08-12       Impact factor: 7.012

Review 2.  Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.

Authors:  Veerle Bieghs; Christian Trautwein
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 3.  Toll-like receptors in liver disease.

Authors:  Jan Petrasek; Timea Csak; Gyongyi Szabo
Journal:  Adv Clin Chem       Date:  2013       Impact factor: 5.394

4.  M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.

Authors:  Jinghong Wan; Merieme Benkdane; Fatima Teixeira-Clerc; Stéphanie Bonnafous; Alexandre Louvet; Fouad Lafdil; Françoise Pecker; Albert Tran; Philippe Gual; Ariane Mallat; Sophie Lotersztajn; Catherine Pavoine
Journal:  Hepatology       Date:  2013-11-20       Impact factor: 17.425

Review 5.  Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.

Authors:  Pierluigi Ramadori; Daniela Kroy; Konrad L Streetz
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

6.  Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.

Authors:  Marta B Afonso; Pedro M Rodrigues; Tânia Carvalho; Marta Caridade; Paula Borralho; Helena Cortez-Pinto; Rui E Castro; Cecília M P Rodrigues
Journal:  Clin Sci (Lond)       Date:  2015-06-15       Impact factor: 6.124

Review 7.  GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.

Authors:  Bertrand Cariou; Bart Staels
Journal:  Expert Opin Investig Drugs       Date:  2014-08-28       Impact factor: 6.206

8.  Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.

Authors:  Michael Kremer; Emmanuel Thomas; Richard J Milton; Ashley W Perry; Nico van Rooijen; Michael D Wheeler; Steven Zacks; Michael Fried; Richard A Rippe; Ian N Hines
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

9.  Role of NKT Cells in the Pathogenesis of NAFLD.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2012-04-05

Review 10.  Immune and inflammatory pathways in NASH.

Authors:  Michal Ganz; Gyongyi Szabo
Journal:  Hepatol Int       Date:  2013-08-30       Impact factor: 6.047

View more
  117 in total

1.  A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Divya P Kumar; Prasanna K Santhekadur; Mulugeta Seneshaw; Faridoddin Mirshahi; Cora Uram-Tuculescu; Arun J Sanyal
Journal:  Hepatology       Date:  2019-03-04       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

3.  Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice.

Authors:  Xianhong Du; Zhuanchang Wu; Yong Xu; Yuan Liu; Wen Liu; Tixiao Wang; Chunyang Li; Cuijuan Zhang; Fan Yi; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Cell Mol Immunol       Date:  2018-05-07       Impact factor: 11.530

Review 4.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

5.  STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis.

Authors:  Yongsheng Yu; Yu Liu; Weishuai An; Jingwen Song; Yuefan Zhang; Xianxian Zhao
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

Review 6.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

7.  Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development.

Authors:  Ralf Weiskirchen; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

Review 8.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

Review 9.  Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases.

Authors:  Charles S Dela Cruz; Min-Jong Kang
Journal:  Mitochondrion       Date:  2017-12-06       Impact factor: 4.160

10.  Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?

Authors:  Priya Handa; Akhila Vemulakonda; Kris V Kowdley; Misael Uribe; Nahum Méndez-Sánchez
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.